Rabbits and rhesus monkeys were injected with 3 x 105 units of human gamma interferon (IFN) prepared in human leukocyte suspensions. Circulating IFN was detected up to 4 h after intravenous administration. Intramuscular injection maintained a relatively stable serum IFN level of about 50 units/ml for 7 to 9 h. The results in both species were similar. Little or no circulating IFN was detected after subcutaneous injection of 3 x 105 units, but 1-5 x 106 units maintained about 50 units per ml of serum for 30 h. Pharmacokinetically, human gamma IFN resembled human alpha interferons rather than human beta IFN. Intramuscular (i.m.) or subcutaneous (s.c.) injections of different human alpha interferons (IFNs) give a long-lasting plateau of circulating IFN in man and several other mammalian species (Cantell et al., 1974; Cantell & Pyh/il~i, 1976; Priestman, 1980; Gutterman et al., 1982a) . On the other haiad, low or non-detectable levels of circulating IFN are obtained after administration of human IFN-fl by the same routes (Edy et al., 1978; Quesada et al., 1982) . Little information is available about the pharmacokinetics of human IFN-~,. Stewart & WiranowskaStewart (1980) reported that human IFN-~ derived from the leukocytes gave roughly similar blood levels as human IFN-~ in mice after i.m. injection. However, recent experiments with natural human IFN-y in man (Gutterman et al., 1982b) and with Escherichia coli-derived human IFN-~ in monkeys (Weck et al., 1982) indicate that very low or non-detectable levels of interferon are attained in the blood after i.m. injection. We now report pharmacokinetic studies in rabbits and monkeys with human IFN-~ prepared in leukocyte suspensions.
Intramuscular (i.m.) or subcutaneous (s.c.) injections of different human alpha interferons (IFNs) give a long-lasting plateau of circulating IFN in man and several other mammalian species (Cantell et al., 1974; Cantell & Pyh/il~i, 1976; Priestman, 1980; Gutterman et al., 1982a) . On the other haiad, low or non-detectable levels of circulating IFN are obtained after administration of human IFN-fl by the same routes (Edy et al., 1978; Quesada et al., 1982) . Little information is available about the pharmacokinetics of human IFN-~,. Stewart & WiranowskaStewart (1980) reported that human IFN-~ derived from the leukocytes gave roughly similar blood levels as human IFN-~ in mice after i.m. injection. However, recent experiments with natural human IFN-y in man (Gutterman et al., 1982b) and with Escherichia coli-derived human IFN-~ in monkeys (Weck et al., 1982) indicate that very low or non-detectable levels of interferon are attained in the blood after i.m. injection. We now report pharmacokinetic studies in rabbits and monkeys with human IFN-~ prepared in leukocyte suspensions.
Leukocyte buffy coats from 100 to 150 blood donors were pooled and the leukocytes were purified by NH4C1 treatment as described previously (Cantell et al., 1981) . The purified leukocytes were suspended in Iscove's modified Dulbecco's medium supplemented with 6 mg of human agamma serum (Cantell et aL, 1981) and 25 ~tg neomycin/ml to give a concentration of 3 × 106 cells/ml. Lens culinaris lectin (R6nnblom et al., 1982) was added to a concentration of 10 ~tg/ml. The lectin was prepared by Dr B. Ersson, Separation Center, University of Uppsala, Uppsala, Sweden. Aliquots of 200 ml of the cell suspension were transferred into 1-1itre polycarbonate bottles which were incubated in a roller (1 rev/min) for 3 days at 36-5 °C. The cells were removed by centrifugation at 1300g for 40 min; the supernatants were the crude IFN-), and they contained about 3000 units/ml.
Polyethylene glycol (PEG) 4000 (Fluka, Buchs, Switzerland) was added to the crude interferon to a concentration of 25%. The suspension was stirred on a magnetic stirrer for 2 h and stored overnight at 4 °C. concentration separates PEG from the liquid phase. The separation took place in a separation funnel during 2 days at 4 °C. The lower liquid phase was collected and solid (NH4)2SO4 was added to a final concentration of 50% and the suspension was kept on a magnetic stirrer for 2 h at 4 °C. The precipitate was sedimented by centrifugation at 13 000 g for 60 rain. It was dissolved in 1/40 vol. (in relation to crude IFN) of 0.1 M-phosphate buffer pH 8.0 on the magnetic stirrer for 3 h. The suspension was centrifuged at 13 000 g for 2 h, dialysed against PBS and centrifuged at 31000 g for 1 h. The supernatant contained 30000 units of IFN-7 (mean of 25 assays) and 73 mg protein/ml. The specific activity was 4 x 102 units/mg protein.
The gamma interferons were routinely assayed by vesicular stomatitis virus (VSV) plaque reduction in human HEp2 cells. A crude preparation of human IFN-~ containing 3000 units/ml served as a laboratory standard. All titres are expressed in terms of this laboratory standard.
The concentrated human IFN-v had about the same activity in human HEp2 and in two monkey cell lines (GMK and Vero). It had no detectable activity (<60 units/ml) in bovine NBL-1 and rabbit RK3 cells. Its activity was not neutralized by a sheep antiserum which contained 450000 neutralizing units against human leukocyte IFN-~ and 3000 neutralizing units against human IFN-fl (Mogensen et al., 1975) . The treatment of the concentrated human IFN-? at pH 2 for 24 h decreased its titre by more than 95 %.
Outbred rabbits (weight 2.9 to 3.3 kg) of a local albino strain and rhesus monkeys (2.0 to 2.8 kg) were used. The animals received 10 ml of the concentrated human IFN-? as an intravenous injection. The i.m. and s.c. injections were given into ten different sites, 1 ml to each site. A rabbit was injected s.c. with 5 ml IFN-v into 10 different sites. Fig. 1 shows the clearance of IFN-7 from blood after intravenous injection of 3 x l0 s units. The results in rabbits and monkeys were similar. The early clearance rate was greatly decreased after 1 to 2 h. Circulating IFN was detected up to 4 h. Intramuscular injection of 3 × 105 units of human IFN-v resulted in detectable amounts of interferon in the blood and a fairly stable level of circulating IFN was maintained up to 9 h in rabbits and 7 h in monkeys (Fig. 2) . Several rabbit serum samples collected during the plateau phase were assayed in bovine and rabbit cells. No interferon activity was detected. Hence, the antiviral activity in the rabbit sera must have been due not to rabbit IFN but to the i.m. injected human IFN-v.
Subcutaneous injection of 3 × 105 units of human IFN-7 did not yield readily detectable levels of circulating interferon. However, a slight reduction of VSV plaque number and size in the IFN assay suggested that the serum samples contained a low level of IFN activity. Therefore, a rabbit was injected with a fivefold higher dose than in the previous experiments. Circulating IFN was now detected and a fairly stable level of about 50 units/ml was maintained up to 30 h.
The IFN injections did not show any overt toxicity to the rabbits or the monkeys. 
